Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 37,837 | 27,482 | 24,215 | 20,254 | 24,565 |
| Cost of Goods | 3,289 | 3,278 | 3,550 | 2,330 | 2,471 |
| Gross Profit | 34,548 | 24,204 | 20,665 | 17,924 | 22,094 |
| Operating Expenses | 53,952 | 51,868 | 62,663 | 55,168 | 50,223 |
| Operating Income | -19,115 | -27,386 | -41,448 | -36,914 | -27,658 |
| Interest Expense | 3,772 | 3,373 | 4,132 | 4,068 | 3,892 |
| Other Income | -3,752 | -3,642 | -3,345 | -2,469 | -3,313 |
| Pre-tax Income | -26,639 | -34,401 | -48,925 | -43,451 | -34,863 |
| Income Tax | -275 | -1,054 | 1,015 | 392 | 2,649 |
| Net Income Continuous | -26,364 | -33,347 | -49,940 | -43,843 | -37,512 |
| Net Income | $-26,364 | $-33,347 | $-49,940 | $-43,843 | $-37,512 |
| EPS Basic Total Ops | -0.53 | -0.69 | -1.05 | -0.92 | -0.76 |
| EPS Basic Continuous Ops | -0.53 | -0.69 | -1.05 | -0.92 | -0.76 |
| EPS Diluted Total Ops | -0.53 | -0.69 | -1.05 | -0.92 | -0.76 |
| EPS Diluted Continuous Ops | -0.53 | -0.69 | -1.05 | -0.92 | -0.76 |
| EPS Diluted Before Non-Recurring Items | -0.54 | -0.69 | -1.05 | -0.92 | -0.80 |
| EBITDA(a) | $-19,115 | $-27,466 | $-42,234 | $-37,616 | $-28,926 |